QuantuMDx Wins UK Funding for Rapid Cancer Dx Tech | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx and its university partners will use funding from the UK's Biomedical Catalyst program to develop and integrate the company's lab-on-a-chip technology into a device for rapidly diagnosing and staging cancers.

The company said on Sunday that it and its partners at the University of Newcastle and the University of Sheffield will use the £1.4 million ($2.2 million) in new funding to support development of a low-cost, sample-to-result benchtop device through an effort called the Q-Cancer project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.